What is the mechanism of action of dacomitinib? How does it exert its therapeutic effects through pharmacological effects?

Dacomitinib is an oral, non-competitive, irreversible tyrosine kinase inhibitor that exerts therapeutic effects mainly by inhibiting epidermal growth factor receptor (EGFR) and its downstream signaling pathways. EGFR is a transmembrane protein that is abnormally activated in a variety of tumor cells and promotes the proliferation, survival and migration of cancer cells. Dacomitinib binds to the tyrosine kinase active site of EGFR, blocks its kinase activity, inhibits the EGFR-mediated signaling pathway, thereby inhibiting the proliferation of cancer cells.

Unlike otherEGFR inhibitors, dacomitinib is an irreversible inhibitor. Traditional reversible inhibitors act by competitively binding to the kinase active site of EGFR, while dacomitinib can bind to the kinase active site persistently to form a stable complex, thereby achieving long-lasting inhibition of the EGFR signaling pathway. Its irreversible effect allows dacomitinib to provide durable inhibitory effects at lower doses, reducing the possibility of drug resistance.

In addition, dacomitinib also has inhibitory effects on multiple HER family receptors (such as HER2 and HER4). This characteristic makes dacomitinib not only outstanding in the treatment of EGFR mutated non-small cell lung cancer (NSCLC), but also has certain potential in the treatment of tumors with HER2 overexpression or HER2 mutation. By inhibiting multiple targets, dacomitinib can effectively cover a wider range of tumor types, thereby improving the breadth and depth of treatment.

The pharmacological effect of dacomitinib is mainly reflected in its inhibition of the growth and proliferation of cancer cells. When treating patients with EGFR mutant non-small cell lung cancer (NSCLC), dacomitinib can effectively control tumor expansion and improve patient survival. Due to its unique mechanism of action, dacomitinib can reduce tumor recurrence and metastasis during treatment and help prolong the progression-free survival of patients (PFS).

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro